Skip to main content
SpringerLink
Log in

Pharmacological Properties of Hirudin and its Derivatives

Potential Clinical Advantages Over Heparin

  • Review Article
  • Drug Therapy
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Summary

Hirudin and its derivatives represent the first parenteral anticoagulants introduced since the discovery of heparin in the early 1900s. Hirudin, the naturally occurring anticoagulant of the leech, is a single peptide chain of 65 amino acids with a molecular weight of about 7000. Recombinant technology has developed methods to produce recombinant forms of hirudin (r-hirudin) in sufficient quantities for therapeutic use.

Hirudin is a potent thrombin-specific inhibitor that forms equimolar complexes with thrombin. It represents a new anticoagulant agent in a field in which heparin has been the only available drug for many years. In contrast to heparin, hirudin does not require antithrombin III as a cofactor, is not inactivated by antiheparin proteins, has no direct effects on platelets and may also inactivate thrombin bound to clot or the subendothelium.

In humans, experience with r-hirudin in preventing or treating venous thromboembolism is very preliminary. However, r-hirudin achieved promising results in patients with unstable angina, or following coronary angioplasty. In patients with acute myocardial infarction, 3 important clinical trials were stopped because of an excess of bleeding complications. At present, the discovery of a r-hirudin regimen that is more efficacious than heparin and at least as safe needs a reappraisal of the drug in further trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Markwardt F. Past, present and future of hirudin. Haemostasis 1991; 21 Suppl. 1: 11–26

    PubMed  CAS  Google Scholar 

  2. Markwardt F, Schäfer G, Töpfer H, et al. Die isolierung des hirudins aus medizinischen blutegeln [in German]. Pharmazie 1967; 22: 239–41

    CAS  Google Scholar 

  3. Bagdy D, Barabas E, Graf L. Large-scale preparation of hirudin. Thromb Res 1973; 2: 229–38

    Article  CAS  Google Scholar 

  4. Baskova IP, Cherkesova DU, Mosolov VV. Hirudin from leech heads and whole leeches and ‘pseudo-hirudin’ from leech bodies. Thromb Res 1983; 30: 459–67

    Article  PubMed  CAS  Google Scholar 

  5. Wallis RB. Hirudins and the role of thrombin: lessons from leeches. Trends Pharmacol Sci 1988; 9: 425–7

    Article  PubMed  CAS  Google Scholar 

  6. Meyer BH, Luus HG, Müller FO, et al. The pharmacology of recombinant hirudin, a new anticoagulant. S Afr Med J 1990; 78: 268–70

    PubMed  CAS  Google Scholar 

  7. Maraganore JM, Bourdon P, Jablonski J, et al. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 1990; 29: 7095–101

    Article  PubMed  CAS  Google Scholar 

  8. Markwardt F. Hirudin and derivatives as anticoagulant agents. Thromb Haemost 1991; 66: 141–52

    PubMed  CAS  Google Scholar 

  9. Markwardt F, editor. Hirudin. Semin Thromb Haemost 1991; 17: 79–159

    Google Scholar 

  10. Editorial. Hirudins: return of the leech? Lancet 1992; 340: 579–80

  11. Bar-Shavit R, Eldora A, Vlodavsky I. Binding of thrombin to subendothelial extracellular matrix: protection and expression of functional properties. J Clin Invest 1989; 84: 1096–104

    Article  PubMed  CAS  Google Scholar 

  12. Stringer KA, Lindenfeld J. Hirudins: antithrombin anticoagulants. Ann Pharmacother 1992; 26: 1535–40

    PubMed  CAS  Google Scholar 

  13. Marckwardt F. Development of hirudin as an antithrombotic agent. Semin Thromb Haemost 1989; 15: 269–82

    Article  Google Scholar 

  14. Marbet GA, Verstraete M, Kienast J, et al. Clinical pharmacology of intravenously administered recombinant desulfatohirudin (CGP 39393) in healthy volunteers. J Cardiovasc Pharm 1993; 22: 364–72

    Article  CAS  Google Scholar 

  15. Verstraete M, Nurmohamed M, Kienast J, et al. Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. J Am Coll Cardiol 1993; 22: 1080–8

    Article  PubMed  CAS  Google Scholar 

  16. Lefkovits J, Topol EJ. Direct thrombin inhibitors in cardiovascular medicine. Circulation 1994; 90: 1522–36

    Article  PubMed  CAS  Google Scholar 

  17. Fox I, Dawson A, Loynds P, et al. Anticoagulant activity of Hirulog™, a direct thrombin inhibitor, in humans. Thromb Haemost 1993; 69: 157–63

    PubMed  CAS  Google Scholar 

  18. Becker RC, Ansell J. Antithrombotic therapy. An abbreviated reference for clinicians. Arch Intern Med 1995; 155: 149–61

    Article  PubMed  CAS  Google Scholar 

  19. Eriksson BI, Kälebo P, Ekman S, et al. Direct thrombin inhibition with rec-hirudin CGP 39393 as prophylaxis of thromboembolic complications after total hip replacement. Thromb Haemost 1994; 72(2): 227–31

    PubMed  CAS  Google Scholar 

  20. Ginsberg JS, Nurmohamed MT, Gent M, et al. Use of hirulog in the prevention of venous thrombosis after major hip or knee surgery. Circulation 1994; 90: 2385–9

    Article  PubMed  CAS  Google Scholar 

  21. Eriksson BI, Kälebo P, Ekman S, et al. A dose-finding trial evaluating the efficacy and safety of three different doses of recombinant hirudin, CGP 39393, (™Revasc-Ciba), in patients undergoing total hip replacement [abstract]. Thromb Haemost 1995; 73: 1108

    Google Scholar 

  22. Ekman S, Eriksson BI, Lindbratt S, et al. Recombinant hirudin, CGP 39393 15 mg (™ Revasc-Ciba), is the most effective and safe prophylaxis of thromboembolic complications in patients undergoing total hip replacement [abstract]. Thromb Haemost 1995; 73: 1093

    Google Scholar 

  23. Doyle DJ, Turpie AGG, Hirsh J, et al. Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis. Ann Intern Med 1987; 107: 441–5

    PubMed  CAS  Google Scholar 

  24. Monreal M, Lafoz E, Ruiz J, et al. Recurrent pulmonary embolism in patients treated because of acute venous thromboembolism: a prospective study. Eur J Vasc Surg 1994; 8: 584–9

    Article  PubMed  CAS  Google Scholar 

  25. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326: 975–82

    Article  PubMed  CAS  Google Scholar 

  26. Parent F, Bridey F, Dreyfus M, et al. Treatment of severe venous thrombo-embolism with intravenous hirudin (HBW 023): an open pilot study. Thromb Haemost 1993; 70(3): 386–8

    PubMed  CAS  Google Scholar 

  27. Schiele F, Vuillemenot A, Kramarz PH, et al. A pilot study of subcutaneous recombinant hirudin (HBW 023) in the treatment of deep vein thrombosis. Thromb Haemost 1994; 71(5): 558–62

    PubMed  CAS  Google Scholar 

  28. Ginsberg JS, Nurmohamed MT, Gent M, et al. Effects on thrombin generation of single injections of hirulog™ in patients with calf vein thrombosis. Thromb Haemost 1994; 72(4): 523–5

    PubMed  CAS  Google Scholar 

  29. Moia M, Schiele F, Walker M, et al. Treatment of acute deep vein thrombosis (DVT) by subcutaneous r-hirudin (HBW 023): a multicentre study [abstract]. Thromb Haemost 1995; 73: 1456

    Google Scholar 

  30. Théroux P, Waters D, Lam J, et al. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992; 327: 141–5

    Article  PubMed  Google Scholar 

  31. Sharma GVRK, Lapsley D, Vita JA, et al. Usefulness and tolerability of hirulog, a direct thrombin-inhibitor, in unstable angina pectoris. Am J Cardiol 1993; 72: 1357–60

    Article  PubMed  CAS  Google Scholar 

  32. LidÓn RM, Théroux P, Juneau M, et al. Initial experience with a direct antithrombin, hirulog, in unstable angina. Anticoagulant, antithrombotic, and clinical effects. Circulation 1993; 88(Pt 1): 1495–501

    Article  PubMed  Google Scholar 

  33. Topol EJ, Fuster V, Harrington RA, et al. Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial. Circulation 1994; 89: 1557–66

    Article  PubMed  CAS  Google Scholar 

  34. Schreiber TL, Rizik D, White C, et al. Randomized trial of thrombolysis versus heparin in unstable angina. Circulation 1992; 86: 1407–14

    Article  PubMed  CAS  Google Scholar 

  35. Théroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988; 319: 1105–11

    Article  PubMed  Google Scholar 

  36. Gruentzig AR, Senning A, Siegenthaler WE. Nonoperative dilation of coronary artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med 1979; 301: 61–71

    Article  Google Scholar 

  37. Topol EJ, Bonan R, Jewitt D, et al. Effect of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 1993; 87: 1622–9

    Article  PubMed  CAS  Google Scholar 

  38. van den Bos AA, Deckers JW, Heyndrickx GR, et al. Safety and efficacy of recombinant hirudin (CGP 39393) versus heparin in patients with stable angina undergoing coronary angioplasty. Circulation 1993; 88(Pt 1): 2058–66

    PubMed  Google Scholar 

  39. Serruys PW, Herrman JPR, Simon R, et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med 1995; 333: 757–63

    Article  PubMed  CAS  Google Scholar 

  40. Bittl JA, Strony J, Brinker JA, et al. Treatment with Bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 1995; 333: 764–9

    Article  PubMed  CAS  Google Scholar 

  41. The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673–82

    Article  Google Scholar 

  42. TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) phase II trial. N Engl J Med 1989; 320: 618–27

    Article  Google Scholar 

  43. Harker LA. Pathogenesis of thrombosis. In: Williams WJ, Beutler E, Erslev AJ, Lichtman MA, editors. Hematology. 4th ed. New York: McGraw-Hill, 1990: 1559–69

    Google Scholar 

  44. Cannon CP, McCabe CH, Henry TD, et al. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 Trial. J Am Coll Cardiol 1994; 23: 993–1003

    Article  PubMed  CAS  Google Scholar 

  45. Lee LV, for the TIMI 6 investigators. Initial experience with hirudin and streptokinase in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 6 Trial. Am J Cardiol 1995; 75: 7–13

    Article  PubMed  CAS  Google Scholar 

  46. Antman EM, for the TIMI 9 investigators. Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9 Trial. Circulation 1994; 90: 1624–30

    Article  PubMed  CAS  Google Scholar 

  47. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994; 90: 1631–7

    Article  Google Scholar 

  48. Neuhaus KL, Essen RV, Tebbe U, et al. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) Study. A study of the Arbeitsgemeinschaft leitender kardiologischer krankenhausärzte (ALKK). Circulation 1994; 90: 1638–42

    Article  PubMed  CAS  Google Scholar 

  49. LidÓn RM, Théroux P, Lespérance J, et al. A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction. Circulation 1994; 89: 1567–72

    Article  PubMed  Google Scholar 

  50. Théroux P, Pérez-Villa F, Waters D, et al. Randomized doubleblind comparison of two doses of hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. Circulation 1995; 91: 2132–9

    Article  PubMed  Google Scholar 

  51. Tripodi A, Chantarangkul V, Arbini AA, et al. Effects of hirudin on activated partial thromboplastin time determined with ten different reagents. Thromb Haemost 1993; 70: 286–8

    PubMed  CAS  Google Scholar 

  52. Monreal M, Monreal L, Ruiz de Gopegui R, et al. Effects of two different doses of hirudin on aPTT, determined with eight different reagents. Thromb Haemost 1995; 73: 219–22

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hospital Universitari Germans Trias i Pujol, Barcelona, Spain

    Manuel Monreal, Joan Costa & Pau Salva

Authors
  1. Manuel Monreal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joan Costa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pau Salva
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Monreal, M., Costa, J. & Salva, P. Pharmacological Properties of Hirudin and its Derivatives. Drugs & Aging 8, 171–182 (1996). https://doi.org/10.2165/00002512-199608030-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199608030-00003

Keywords

Search

Navigation